From Confusion to Clarity: Meet the “ChatGPT for Blood”
When flashy claims around blood diagnostics often spark skepticism, one startup is winning trust by doing things differently; through transparency, clinical rigor, and actual traction.
Meet BloodGPT, a healthtech company based in Cyprus, on a mission to make lab results as easy to understand as a conversation. Described as the “ChatGPT for blood,” BloodGPT is already delivering real results: its platform turns complex blood test data into clear, actionable insights in under two minutes and over 500 paying customers are already using it.
Who’s Behind BloodGPT?
The team combines decades of experience in healthcare, AI, and entrepreneurship:
Vasilii Lazuka, CEO & co-founder, previously built and exited a successful enterprise software company.
Nikita Udovichenko, CMO & co-founder, is a trained biochemist and serial founder with a strong background in endocrinology.
Nata Savaścienka, Head of Product, brings deep expertise in enterprise AI and software design.
Jonathan Kron, Strategic advisor, guides various healthcare institutions and management boards.
A Solution for Both Doctors and Patients
Launched on June 16, 2025, BloodGPT's AI-powered tool aims to lighten the load for healthcare professionals while easing patient anxiety. Currently, doctors spend an average of 4–7 hours a week reviewing lab reports. BloodGPT promises to cut that down to just 30 minutes, freeing up more time for meaningful care.
At its core, the platform caters to both sides of the healthcare equation:
Doctors receive AI pre-analyzed lab results alongside clinical decision support tools that are transparent and editable.
Patients gain access to visually simplified data, personalized health trends, and easily digestible explanations of what their blood work means.
By using both GPT and Gemini models to cross-verify results, BloodGPT ensures that every insight is backed by up to date medical knowledge and clear reasoning. (1)
What Sets BloodGPT Apart
Unlike many health chatbots that merely repackage general purpose AI, BloodGPT is custom built for clinical use with a multi agent architecture tailored to handle medical data.
Key Features:
Instant blood test interpretation in 98 languages and formats.
Trend tracking across multiple timepoints and test types.
Clinician tools that offer explainable AI suggestions, which can be reviewed and modified by professionals.
Integration ready design compatible with major hospital and lab systems, including InterSystems (used in 150+ countries).
Funding and What’s Next
BloodGPT has raised $1 million at a $10 million valuation, with the current round expected to close by the end of June. The company was initially bootstrapped by its founders but is now looking to bring in strategic investors who can support their global B2B expansion.(2)
(Rh/Dr. Hansini Bhaskaran/MSM)
